Maria Stepanova
Overview
Explore the profile of Maria Stepanova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
208
Citations
5523
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Younossi Z, Stepanova M, Younossi I, Racila A
JHEP Rep
. 2025 Feb;
7(3):101276.
PMID: 39980748
Background & Aims: The new nomenclature for metabolic dysfunction-associated steatohepatitis (MASH) requires presence of steatohepatitis in the context of at least one cardiometabolic risk. Having a health-related quality of life...
3.
Younossi Z, Paik J, Henry L, Pollock R, Stepanova M, Nader F
Ann Hepatol
. 2025 Feb;
30(2):101789.
PMID: 39929473
Introduction And Objectives: Non-invasive tests (NITs) identifying high-risk MASLD in primary care is suggested but, these strategies cost-effectiveness remain uncertain in the United Kingdom (UK). Materials And Methods: A cost-utility/budget...
4.
Younossi Z, de Avila L, Racila A, Nader F, Paik J, Henry L, et al.
Hepatology
. 2025 Jan;
PMID: 39879587
Background And Aims: There is a paucity of data about the prevalence of cirrhosis and portal hypertension in the US general population. Approach And Results: We used National Health and...
5.
Younossi Z, Estep J, Felix S, Lam B, Younossi Z, Racila A, et al.
Diabetes Res Clin Pract
. 2024 Dec;
219():111960.
PMID: 39675485
Background: Association of genetic factors with non-invasive tests (NITs) for MASLD has not been well established. Methods: Clinical and laboratory data, liver biopsy and/or liver stiffness measurement (LSM) by transient...
6.
Younossi Z, Stepanova M
J Hepatol
. 2024 Oct;
82(2):e105-e106.
PMID: 39454690
No abstract available.
7.
Younossi Z, Paik J, Henry L, Stepanova M, Nader F
Liver Int
. 2024 Oct;
45(4):e16119.
PMID: 39373093
Background And Aims: Several scientific associations recommend a sequential combination of non-invasive tests (NITs) to identify high-risk MASLD patients but their cost-effectiveness is unknown. Methods: A cost-utility model was developed...
8.
Alqahtani S, Yilmaz Y, El-Kassas M, Alswat K, Mawardi M, Sanai F, et al.
Ann Hepatol
. 2024 Sep;
30(1):101569.
PMID: 39276988
Introduction And Objectives: Given the substantial burden of metabolic dysfunction-associated steatotic liver disease (MASLD), there is an urgent need to assess knowledge and awareness levels among physicians. We assessed MASLD...
9.
Younossi Z, Stepanova M, Racila A, Henry L, Labriola D, Taub R, et al.
Hepatology
. 2024 Sep;
PMID: 39250515
Background And Aims: Resmetirom, liver-directed thyroid-hormone receptor-β agonist, received approval for metabolic dysfunction-associated steatohepatitis (MASH) treatment. We assessed health-related quality of life (HRQL) in patients with MASH treated with resmetirom....
10.
Alqahtani S, Alswat K, Mawardi M, Sanai F, Abaakhail F, Alghamdi S, et al.
Saudi J Gastroenterol
. 2024 Aug;
30(5):335-341.
PMID: 39175281
Background: A recent name change of nonalcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated fatty liver disease (MAFLD) to metabolic dysfunction-associated steatotic liver disease was primarily driven by potential stigma...